Adagene Inc. (FRA:978)
Germany · Delayed Price · Currency is EUR | Market Cap | 144.50M +104.6% |
| Revenue (ttm) | 8.13M +8,902.4% |
| Net Income | -17.95M |
| EPS | -0.35 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 2.100 |
| Previous Close | 2.060 |
| Day's Range | 2.080 - 2.100 |
| 52-Week Range | 1.180 - 4.040 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Adagene
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ... [Read more]
Financial Performance
In 2025, Adagene's revenue was $7.67 million, an increase of 7332.76% compared to the previous year's $103,204. Losses were -$17.61 million, -47.32% less than in 2024.
Financial numbers in USD Financial StatementsNews
Adagene Transcript: Chardan's 10th Annual Healthcare Conference
Phase II ADG126 data are expected in H1 2027, with a potential randomized Phase III and OS endpoint to follow. A Singapore neoadjuvant study is testing a loading-dose regimen, with data expected in 2027; cash runway extends to H2 2028.
Adagene Transcript: H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
ADG138’s dual masking is intended to widen the safety window for HER2×CD3 T-cell engagement, with first-in-human dosing planned in 2026. Muzastotug MSS CRC Phase II data are targeted for H1 2027, alongside additional clinical updates.
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel ...
Adagene announces China’s NMPA approved IND for ADG138
Adagene (ADAG) announced that China’s National Medical Products Administration, NMPA, has approved the company’s investigational new drug, IND, application for ADG138, a double-masked HER2xCD3 bispeci...
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary S...
Adagene Transcript: H.C. Wainwright 28th Annual Global Investment Conference
ADG126, enabled by SAFEbody technology, demonstrates high-dose safety and promising efficacy in late-line colorectal cancer, with pivotal phase II and III trials planned. Strategic collaborations and a strong pipeline, including ADG138, support growth, backed by recent capital raises.
Adagene Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
SAFEbody technology and ADG126 show promising efficacy and safety in MSS CRC, with response rates up to 36% and low discontinuation rates. Collaborations with Incyte and Sanofi expand clinical reach, while a strong cash position supports trials through 2028.
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
Adagene initiated with a Buy at Chardan
Chardan initiated coverage of Adagene (ADAG) with a Buy rating and $9 price target Adagene is a clinical stage company developing its lead asset, muzastotug, in late line colorectal cancer,…
Adagene announces $2M milestone payment from Exelixis
Adagene (ADAG) announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis (EXEL). The milestone achievement is related to a preclinical milestone event f...
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developm...
Adagene Slides: Corporate presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Adagene to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel ...
Adagene Earnings release: Q2 2026
Adagene released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has...
Adagene Slides: Corporate presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The session highlighted advances in masked antibody technology, with ADG126 showing strong efficacy and safety in late-line MSS-CRC. Strategic collaborations with Incyte and Sanofi expand development into new combinations and tumor types, supported by a recent $70M financing.
Adagene Slides: Investor presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based thera...
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
Adagene (ADAG) presented new data from two ongoing Phase 1b/2 studies of muzastotug in triple combination regimens at the American Association of Cancer Research annual meeting 2026, held April 17-22…
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively...
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developm...
Adagene price target raised to $10 from $9 at Guggenheim
Guggenheim raised the firm’s price target on Adagene (ADAG) to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings,…
Adagene Slides: Investor presentation
Adagene has posted slides in relation to its latest quarterly earnings report, which was published on April 3, 2026.
Adagene 18.666M share Spot Secondary priced at $3.75
Leerink and LifeSci Capital acted as joint book running managers for the offering.